RxDoctor Payments Data

Clotilde Hainline, MD

Neurology · Boston, MANPI 1447539432

Payments from drug & device makers

$247,237in general payments, 2019–2025

Across 141 payments — averaging $1753.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$211K
  • Roche Products Limited$21K
  • Genentech USA, Inc.$8K
  • TG Therapeutics, Inc.$4K
  • Novartis$2K
  • Amgen$383
  • plus $719 from 4 others

What the payments were for

  • Consulting fees$9,37571%
  • Travel & lodging$1,77814%
  • Food & beverage$1,88414%
  • Education$1081%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Genentech, Inc.26$211,083
Roche Products Limited28$21,475
Genentech USA, Inc.8$8,020
TG Therapeutics, Inc.6$3,504
Novartis40$2,054
Amgen(2 entities)7$383
Biogen17$369
EMD Serono, Inc.3$198
Sanofi5$119
E.r. Squibb & Sons, L.L.C.1$32

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$247,237 in reported general payments places this provider in the 85th percentile of 761 neurology providers in Massachusetts.

See all neurology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$20,674
Medicare patients
130
Services billed
196

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab21$201,515
AubagioTeriflunomide17$153,773
TecfideraDimethyl Fumarate13$118,529
Teriflunomide40$115,401
PlegridyPeginterferon Beta-1a14$110,399
MayzentSiponimod12$108,217
Dalfampridine ErDalfampridine105$44,804
FingolimodFingolimod Hcl34$29,913
MyrbetriqMirabegron46$25,770
LinzessLinaclotide19$12,141
Aimovig AutoinjectorErenumab-Aooe16$11,755
Dimethyl Fumarate21$6,381
Baclofen175$2,709
Gabapentin119$2,379
Oxcarbazepine31$1,461

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenTecfidera, Plegridy$369$228,92827 claims
SanofiAubagio$119$153,77317 claims
NovartisMayzent$2,054$108,21712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 761 neurology providers in Massachusetts.

Other neurology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →